menu

Medical Program: Emerging Roles for Immunotherapy in HER2+ Breast Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Emerging Roles for Immunotherapy in HER2+ Breast Cancer

close
Emerging Roles for Immunotherapy in HER2+ Breast Cancer
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • Sponsored by

  • Overview

    What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting. 

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/23/20